KR20210084509A - 항체 라이브러리 및 방법 - Google Patents

항체 라이브러리 및 방법 Download PDF

Info

Publication number
KR20210084509A
KR20210084509A KR1020217015023A KR20217015023A KR20210084509A KR 20210084509 A KR20210084509 A KR 20210084509A KR 1020217015023 A KR1020217015023 A KR 1020217015023A KR 20217015023 A KR20217015023 A KR 20217015023A KR 20210084509 A KR20210084509 A KR 20210084509A
Authority
KR
South Korea
Prior art keywords
antibody
variant
amino acid
dna
xaa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217015023A
Other languages
English (en)
Korean (ko)
Inventor
리처드 뷰익
크리스토퍼 스캇
다라 맥칸
리오나 맥거
휴 모건
나타샤 캠벨
제임스 맥클로리
앤서니 오카네
Original Assignee
퓨전 안티바디스 피엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1817188.4A external-priority patent/GB201817188D0/en
Priority claimed from GBGB1904754.7A external-priority patent/GB201904754D0/en
Priority claimed from GBGB1905032.7A external-priority patent/GB201905032D0/en
Application filed by 퓨전 안티바디스 피엘씨 filed Critical 퓨전 안티바디스 피엘씨
Publication of KR20210084509A publication Critical patent/KR20210084509A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1089—Design, preparation, screening or analysis of libraries using computer algorithms
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B10/00—Directed molecular evolution of macromolecules, e.g. RNA, DNA or proteins
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020217015023A 2018-10-22 2019-10-22 항체 라이브러리 및 방법 Pending KR20210084509A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1817188.4A GB201817188D0 (en) 2018-10-22 2018-10-22 Antibody library
GB1817188.4 2018-10-22
GB1904754.7 2019-04-04
GBGB1904754.7A GB201904754D0 (en) 2019-04-04 2019-04-04 Antibody library and method
GBGB1905032.7A GB201905032D0 (en) 2019-04-09 2019-04-09 Antibody library and method
GB1905032.7 2019-04-09
PCT/GB2019/053010 WO2020084298A1 (en) 2018-10-22 2019-10-22 Antibody library and method

Publications (1)

Publication Number Publication Date
KR20210084509A true KR20210084509A (ko) 2021-07-07

Family

ID=68393020

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217015023A Pending KR20210084509A (ko) 2018-10-22 2019-10-22 항체 라이브러리 및 방법

Country Status (10)

Country Link
US (2) US12378696B2 (https=)
EP (1) EP3870607A1 (https=)
JP (2) JP7853096B2 (https=)
KR (1) KR20210084509A (https=)
CN (1) CN113195537A (https=)
AU (1) AU2019365135A1 (https=)
BR (1) BR112021007529A2 (https=)
CA (1) CA3115150A1 (https=)
MX (1) MX2021004149A (https=)
WO (1) WO2020084298A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7473339B2 (ja) * 2017-03-07 2024-04-23 エフ． ホフマン－ラ ロシュ アーゲー 代替の抗原特異的抗体変異体を発見するための方法
CN112289369B (zh) * 2020-12-15 2021-04-02 武汉华美生物工程有限公司 一种基于深度学习的抗体库构建方法及装置
CN114775065B (zh) * 2022-04-22 2026-01-06 武汉华美生物工程有限公司 一种半合成纳米抗体库构建方法和纳米抗体库
CN115171774A (zh) * 2022-05-17 2022-10-11 慧壹科技(上海)有限公司 一种抗体/大分子药物的亲和力改造系统和方法
CN117736329B (zh) * 2023-12-25 2024-11-12 华润生物医药有限公司 抗pd-1抗体及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2011801A1 (en) * 1999-05-27 2009-01-07 Government of the United States as represented by the Secretary, Department of Health and Human Services Immunoconjugates having high binding affinity
WO2016188911A1 (en) * 2015-05-22 2016-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies fragments inhibiting both the cath-d catalytic activity and its binding to the lrp1 receptor
CN109576292B (zh) * 2018-12-21 2022-11-29 深圳市爱思迪生物科技有限公司 一种抗体文库的构建方法及其应用

Also Published As

Publication number Publication date
WO2020084298A1 (en) 2020-04-30
MX2021004149A (es) 2021-06-15
EP3870607A1 (en) 2021-09-01
CN113195537A (zh) 2021-07-30
US20250382726A1 (en) 2025-12-18
CA3115150A1 (en) 2020-04-30
BR112021007529A2 (pt) 2021-08-03
US20210388063A1 (en) 2021-12-16
JP2026016427A (ja) 2026-02-03
JP2022512650A (ja) 2022-02-07
JP7853096B2 (ja) 2026-04-28
AU2019365135A1 (en) 2021-05-13
US12378696B2 (en) 2025-08-05

Similar Documents

Publication Publication Date Title
KR20210084509A (ko) 항체 라이브러리 및 방법
Traxlmayr et al. Construction of a stability landscape of the CH3 domain of human IgG1 by combining directed evolution with high throughput sequencing
WO2022104918A1 (zh) 针对冠状病毒具有中和活性的双特异性抗体及其用途
KR20190134614A (ko) B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도
JP2018504410A (ja) 非免疫原性単一ドメイン抗体
WO1999055369A1 (en) Monoclonal antibodies with reduced immunogenicity
KR101763345B1 (ko) 단백질 조합 기반의 Fv 라이브러리 및 이의 제조 방법
US20170088611A1 (en) Single-chain multivalent binding protein compositions and methods
US20170183395A1 (en) Rodent combinatorial antibody libraries
JP2020517718A (ja) 抗体の選択方法
KR20230015957A (ko) 이중특이적 항체 및 이의 용도
Fennell et al. Dissection of the IgNAR V domain: molecular scanning and orthologue database mining define novel IgNAR hallmarks and affinity maturation mechanisms
CN112703204B (zh) 针对可溶性bcma的抗体
EP2501808A1 (en) Display of disulfide linked dimeric proteins on filamentous phage
JP2026508171A (ja) 共通軽鎖抗体ライブラリーとその調製方法及び用途
CA3218187A1 (en) Fc mutant with altered binding to fc receptor
US20110245100A1 (en) Generation of antibodies to an epitope of interest
US20130045895A1 (en) Binding domains
TW202532437A (zh) Cfc1結合分子
CN119855835A (zh) 基于共同轻链产生双特异性抗体的方法
WO2026059472A1 (en) Bivalent bispecific antibody and method for producing thereof
KR20220087488A (ko) Pd-l1 결합 분자
CN119735680A (zh) 一种抗cd28的单克隆抗体及细胞

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902